Related Experiment Video
Updated: Dec 30, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Peptide decoys: a new technology offering therapeutic opportunities for breast cancer
Maryam Mahjoubin-Tehran1, Samaneh Rezaei2, Amin Jalili2
1Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract:
Breast cancer is the most common cancer among women. Absence of hormone receptors (estrogen and progesterone) and lack of overexpression of Human Epidermal Growth Factor 2 (HER2) make triple-negative breast cancer (TNBC) an aggressive subtype of breast cancer that is resistant to conventional therapies. Peptide decoys have emerged as a novel therapeutic approach for the treatment of breast cancer. Decoy peptide technology entails the use of soluble proteins or peptides, including binding proteins or inactive cell surface receptors. Peptide decoys bind to certain ligands (e.g., inflammatory cytokines) with high affinity and specificity as receptors but cannot initiate any signaling pathway that is involved in the pathogenesis of breast cancer. In this review, we discuss the use of decoy peptides as a novel therapeutic approach for breast cancer treatment.
Insights
Peptide decoys offer a new treatment for triple-negative breast cancer (TNBC), an aggressive form resistant to standard therapies. These decoys bind to disease-driving molecules without triggering harmful signals, presenting a promising therapeutic strategy.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype lacking hormone receptors and HER2 overexpression.
- TNBC exhibits resistance to conventional therapeutic strategies.
- Novel therapeutic approaches are crucial for improving TNBC treatment outcomes.
Purpose of the Study:
- To review the potential of peptide decoys as a novel therapeutic strategy for breast cancer.
- To discuss the mechanism of action of decoy peptide technology.
- To highlight the application of peptide decoys in treating aggressive breast cancer subtypes like TNBC.
Main Methods:
- Review of existing literature on peptide decoys and breast cancer therapy.
- Analysis of decoy peptide technology principles, including binding affinity and specificity.
- Examination of signaling pathways involved in breast cancer pathogenesis.
Main Results:
- Peptide decoys function as soluble binding proteins or inactive receptors.
- They exhibit high affinity and specificity for disease-related ligands.
- Crucially, peptide decoys do not initiate downstream signaling pathways involved in cancer progression.
Conclusions:
- Decoy peptide technology represents a promising and novel therapeutic avenue for breast cancer treatment.
- This approach offers a potential strategy to overcome resistance seen in aggressive subtypes like TNBC.
- Further research and development in decoy peptides could lead to more effective breast cancer therapies.
More Related Videos
09:06Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
Published on: February 3, 2023
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
